Summary

This article discusses results from the Phase 2 dose-ranging RE-DEEM Trial, as well as results of a post hoc analysis of data from the RE-LY Trial.

  • Cerebrovascular Disease
  • Cerebrovascular Disease Clinical Trials
  • Arrhythmias
  • Myocardial Infarction
View Full Text